Market Overview

Looking Into Teva Pharmaceutical Indus's Return On Capital Employed


Looking at Q2, Teva Pharmaceutical Indus (NYSE: TEVA) earned $172.00 million, a 9.95% increase from the preceding quarter. Teva Pharmaceutical Indus's sales decreased to $3.87 billion, a 11.18% change since Q1. Teva Pharmaceutical Indus earned $191.00 million, and sales totaled $4.36 billion in Q1.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Teva Pharmaceutical Indus’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Teva Pharmaceutical Indus posted an ROCE of 0.01%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Teva Pharmaceutical Indus's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q2 Earnings Recap

Teva Pharmaceutical Indus reported Q2 earnings per share at $0.55/share, which beat analyst predictions of $0.53/share.


Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Earnings News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at